Hisun Pharmaceutical To Set Up Overseas Subsidiary
This article was originally published in PharmAsia News
Zhejiang Hisun Pharmaceutical has announced plans to set up a wholly-owned subsidiary abroad; however, location details and investment amounts were not released. The team entrusted with managing the project will kick-start the plan depending on market conditions and the company's performance. Board members of Hisun believe the move will expand the firm's product sales globally, strengthen its drug registration work and help it stay abreast of the latest international business information. The establishment of a new overseas branch will raise the company's overall profit and risk-taking capacity. In addition, Hisun is reorganizing its management structure and implementing strategic business units to meet development needs. (Click here for more - Chinese Language)
You may also be interested in...
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.